Aura Biosciences appoints Jeremy Bender to Board of Directors; updates director compensation policy
Aura Biosciences, Inc.
Jeremy Bender, Ph.D., M.B.A., appointed as Class II director effective July 7, 2026; term expires at 2029 annual meeting.
Bender appointed to Compensation Committee and Nominating and Corporate Governance Committee.
Received initial option award for 60,000 shares and RSU award for 30,000 shares, vesting over three years.
Board amended Non-Employee Director Compensation Policy on June 11, 2026, increasing initial option award from 34,000 to 60,000 shares and annual option award from 17,000 to 30,000 shares.
Bender previously CEO of Day One Biopharmaceuticals, led acquisition by Servier for ~$2.5B in 2026.
On July 3, 2026, the Board of Directors (the “Board”) of Aura Biosciences, Inc. (the “Company”) increased the size of the Board from six to seven directors and unanimously appointed Jeremy Bender, Ph.D., M.B.A., as a Class II director, effective July 7, 2026 (the “Effective Date”), to fill the newly created vacancy.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Jeremy Bender was appointed as Class II Director at Aura Biosciences, Inc..
Action
appointed
Role
Class II Director
Exact text from the filing
On July 3, 2026, the Board of Directors (the “Board”) of Aura Biosciences, Inc. (the “Company”) increased the size of the Board from six to seven directors and unanimously appointed Jeremy Bender, Ph.D., M.B.A., as a Class II director, effective July 7, 2026 (the “Effective Date”), to fill the newly created vacancy.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.